NAD+ • cellular chemistry and human evidence
NAD+ is a coenzyme that helps cells transfer energy and carry out essential enzyme reactions. It is not a peptide, an energy drink or a GLP-1 drug. Your body makes and recycles it. Some supplements raise blood NAD-related measurements, but that alone does not show that they improve fatigue, remove belly fat or slow human aging.
Human research has moved beyond the first small infusion studies. New randomized trials report results for a particular oral NAD+ formulation and for specific diseases. The useful question is what changed, in whom, and whether the result belongs to NAD+ itself, NR or NMN.
For laboratory material, configurations and published analytical records, see the NAD+ research reagent page. The clinical preparations discussed here are separate from Apex’s in-vitro research material.
What is NAD+?
NAD stands for nicotinamide adenine dinucleotide. Two nucleotide-containing parts are joined through phosphate groups. The plus sign identifies its oxidized redox form; NADH is the reduced partner. Both forms participate in metabolism. Calling NAD+ the “active” form and NADH inactive would miss the point of the pair.
NAD+ is also different from vitamin B3. Nicotinic acid and nicotinamide are B3 forms that can supply material for NAD synthesis. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) enter related precursor pathways. None of these names makes the molecules interchangeable. Their absorption, conversion and tested clinical outcomes differ. Human precursor review.
NAD+
The oxidized coenzyme. A reference free-acid formula is C21H27N7O14P2, approximately 663.43 g/mol; CAS 53-84-9. Check salt, water and material basis on an actual specification.
NADH
The reduced redox partner. A trial of NADH cannot automatically answer a question about administered NAD+, even when a review groups them together.
NR and NMN
Precursors used to build NAD-related pools. A rise after one precursor does not establish that a direct NAD+ product produces the same effect.
Reference identity: PubChem, Nadide. Molecular weight is not a concentration, an assay result or a recommended amount to use.
How does NAD+ work in cells?
NAD+ has two central jobs. It carries reducing equivalents in energy metabolism, and it is used up by enzymes involved in signaling, DNA-damage responses and protein regulation. Those are different reactions, with different consequences for the cell’s NAD pool.
Transfer and recycle
NAD+ accepts a hydride in redox chemistry; NADH can donate reducing equivalents in other reactions. The pair helps connect nutrient oxidation to cellular energy production.
The coenzyme cycles between forms. It is not itself a packet of calories.
Consume and rebuild
Sirtuins, PARPs and CD38-family enzymes cleave NAD+ during their reactions. Nicotinamide, abbreviated NAM, can be recycled through salvage pathways.
These enzymes have distinct functions. “More NAD+” does not specify which function changed.
The early sirtuin story illustrates why the mechanism needs context. A 1999 yeast study connected Sir2-related processes with mother-cell lifespan. A 2001 human-cell study showed SIRT1-dependent deacetylation of p53, including reduced p53 transcriptional activity. That is a specific regulatory effect, not evidence that universally increasing this pathway is beneficial.
Likewise, the 2003 resveratrol–sirtuin report cannot stand alone. A 2010 study using native substrates challenged apparent direct activation obtained with fluorophore-linked assay substrates. These experiments concern assay conditions and sirtuin activation; they do not prove that NAD+, resveratrol or their combination extends human life.
How does the body maintain its NAD+ pool?
A concentration is a snapshot, not a measurement of how quickly all those reactions are running. The same concentration can coexist with different rates of synthesis and consumption. Blood, liver, muscle and brain are also not one freely interchangeable container. Reviews of in-vivo NAD biology and precursor research provide useful background, but their older clinical summaries need to be read alongside newer trials.
A 2026 comparison in 65 healthy adults found that NR and NMN raised circulating NAD-related levels after repeated use, while nicotinamide’s response differed. The accompanying experiments showed substantial precursor conversion by human-donor gut microbes outside the body. Those culture experiments help explain possible routes; they are not direct tracking of every administered molecule through a living person.
Does NAD+ decline with age—and can a blood test tell?
Age-related NAD changes are important in experimental biology, but the answer depends on the tissue and measurement. Diabetic and aging mouse work, worm longevity experiments, old-mouse mitochondrial studies and CD38 experiments established influential hypotheses. They do not establish a universal percentage decline in human blood or prove that replacing NAD slows human aging.
2022 • 1,518 people
A sex-dependent blood pattern
A community study reported associations that differed between men and women rather than one uniform age curve. Its cross-sectional design compared different people; it did not track each person’s decline over a lifetime.
2026 • seven cohorts
A direct counterexample
A validated mass-spectrometry study found whole-blood NAD+ stable across age and the studied lifestyle interventions, while still detecting a response to NR supplementation. This challenges blood NAD+ as a general aging or lifestyle biomarker.
The 2026 result does not show that all tissues remain unchanged. It does mean that statements such as “everyone loses half their NAD+ by middle age” need a tissue, method and supporting human dataset. A blood result is not automatically a measure of brain NAD+, mitochondrial function or biological age.
Three questions for any NAD test
What sample? Whole blood, plasma, isolated cells and a tissue biopsy answer different questions. What analyte? An assay of NAD+ alone differs from total NAD+ plus NADH. What validated interpretation? A laboratory reference range does not by itself establish a treatment threshold or a target for better health.
What do direct NAD+ studies show in humans?
Direct NAD+ now has randomized human studies as well as pilot and retrospective reports. Results remain tied to the formulation, route, population and endpoint tested. Three recent examples make that distinction concrete.
Oral LNAD+: a large blood-marker change, without demonstrated clinical benefit
The July 2026 RENEWAL-NAD+ publication studied a proprietary NAD+ formulation containing polyethylene glycol, not an ordinary unspecified NAD+ supplement. It randomized 60 adults aged 45–75. Fifty-one were in the reported sensitivity set and 50 in the primary analysis, after one placebo participant was excluded following unblinding. That difference matters when judging how complete the evidence is.
Whole blood • day 6
+53%Adjusted comparison
The reported between-group increase was in an assay of total NAD, including NADH. Whole-blood results predominantly reflect red-cell pools.
Separated plasma
No changeDifferent compartment
The plasma endpoint was not significantly changed. A whole-blood result cannot be relabeled as an increase throughout the body.
Health and wellbeing
Not shownDifferent question
No secondary clinical, vital-sign, wellbeing or wearable endpoint survived the study’s multiple-testing correction.
The intervention lasted five days. It therefore does not establish durable benefit, slowed aging or long-term safety. No isotope tracing established whether NAD+ entered cells intact or was broken down and rebuilt. The formulation’s detailed manufacturing characterization was proprietary, and the sponsor funded the trial; several authors disclosed consulting, shares or options.
The registry record lists completion in June 2022 and first public posting on January 13, 2026. The paper acknowledges retrospective registration. This is a reason to examine the original protocol and analysis history, not a reason to erase the observed result.
Heart failure: a ventricular-function signal, without a proven event reduction
A 180-person randomized trial studied a short IV NAD+ course added to standard treatment in ischemic cardiomyopathy-related heart failure. At one month, left-ventricular ejection fraction improved more in the NAD+ group. Ejection fraction is the percentage of blood expelled from the ventricle with a beat; it is not a percentage reduction in the chance of heart failure.
Mean change from baseline • percentage points
Both bars use a 0–5 percentage-point scale. The difference in change was 2.24 points; reported P=.023. These are changes, distinct from final mean ejection fractions of 45.44% and 42.44%.
At six months, the composite of major cardiac/cerebrovascular events was 14.6% versus 24.7%, but the difference was not statistically significant (P=.089). Heart-failure hospitalization also did not meet significance. The trial therefore supports further study of a functional signal, not a claim that NAD+ prevents cardiovascular events or replaces standard care.
An earlier heart-failure study randomized 60 people and analyzed 58. Its comparisons of ejection-fraction and NT-proBNP improvement rates were not statistically significant. A separate analysis of the NT-proBNP trajectory reported P=.035. These are different statistical questions, so describing every cardiac outcome as either positive or null would be misleading. The study also reported oxidative-stress-related changes and acknowledged retrospective registration.
Sudden hearing loss: a small disease-specific finding
A 2026 report compared intramuscular NAD+ plus standard treatment with standard treatment for sudden sensorineural hearing loss. Forty-five people were randomized, but 38 completed the study and were analyzed: 18 versus 20. Mean pure-tone hearing improvement was 40.21 versus 23.06 dB HL. That is a hearing-test outcome in a specific illness, not evidence for general cognitive enhancement.
The reported 94.4% “effective” rate included lesser degrees of improvement; it was not a 94.4% complete-recovery rate. Attrition, the single-center setting and limited masking detail warrant caution. The methods do not describe a matching control injection. The registry entry remains outdated: its September 2026 retrieval showed unknown status and estimated enrollment of 36, while the paper reports 45 randomized. It is neither a second replication nor a current recruitment announcement.
What the earlier infusion work can—and cannot—answer
The 2019 pilot randomized eight men to NAD+ and three to saline, following plasma and urinary metabolites during and shortly after infusion. Plasma NAD+ did not rise during the first two hours. Removal from plasma does not prove intact entry into every tissue, and this sampling schedule does not establish a general human half-life or an anti-aging effect.
A 2026 commercial-clinic chart review compared six NAD+ clients with eight NR clients. It was retrospective, without a placebo or matched control group; all authors were employed by the clinic company. Infusion tolerability differed, but exploratory metabolic changes over 30 days do not demonstrate durable health benefits. The two interventions should not be collapsed into one “NAD therapy” result.
NAD+ versus NR and NMN: what do precursor trials add?
NR and NMN have human trials showing increases in NAD-related blood measurements. The 2016 NR pharmacokinetic work, an eight-week NR trial and a 30-person, twelve-week NMN trial are examples. Their results establish biochemical responses in the tested settings, not a blanket clinical benefit for all products or populations.
Clinical outcomes are mixed. Some findings deserve follow-up; others show that a large biomarker response can coexist with a disappointing functional result.
On a narrow screen, scroll the table horizontally. Keyboard users can focus the table and use the arrow keys.
| Material and study | People and design | Measured finding | What remains limited |
|---|---|---|---|
| NMN 2021 metabolic trial | 25 postmenopausal women with prediabetes completed a 10-week placebo-controlled trial. | Muscle insulin sensitivity improved; body fat, visceral fat and body weight did not. | A small, selected population. Baseline liver fat differed between groups. This is not a weight-loss trial result for NAD+. |
| NR 2024 NICE trial | 90 adults with peripheral artery disease, three groups, six months. | NR versus placebo: adjusted 17.6 m advantage in six-minute walking distance. | P=.08 met the trial’s prespecified one-sided .10 threshold. It is not a conventional two-sided P<.05 result. Adding resveratrol gave no clear additional benefit. |
| NR 2025 long-COVID trial | 58 randomized; placebo switched to NR after ten weeks. | Blood NAD+ rose approximately 2.6–3.1-fold with NR. | No significant between-group benefit for cognition, fatigue, sleep or mood. High, unequal attrition further limits confidence. |
Sources: NMN metabolic trial and its published baseline-imbalance critique; NICE trial; long-COVID randomized trial. The NMN authors’ response notes that muscle insulin sensitivity was balanced at baseline and argues that liver-fat imbalance does not negate the muscle finding. The debate warrants attention; it does not turn that finding into weight loss. A favorable within-group change is weaker than a clear randomized comparison, particularly when outcomes are selected after the analysis.
There is no universal winner implied by “closer to NAD+” in a pathway diagram. Product formulation, absorption, conversion, tissue access and the clinical problem all matter. A short comparison of blood markers cannot establish which precursor makes healthy people feel better or live longer.
NAD+ side effects, injections and product quality
Being naturally present in cells does not establish the safety of an administered preparation. Route and formulation can change exposure, tolerability and contamination risk. Short studies also cannot establish uncommon or long-latency harms.
Infusion tolerability
The six NAD+ clients in the 2026 chart review reported substantial gastrointestinal symptoms and other discomfort, including increased heart rate and chest pressure, during administration. Symptoms resolved when infusions ended. This is an observed small cohort, not a population-wide side-effect rate.
Compounding and endotoxin risk
FDA has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injections, sometimes requiring treatment. The agency describes these as consistent with excessive endotoxins and warns against using food-grade material for sterile compounding without appropriate processing.
Those are distinct concerns: a tolerability signal does not prove contamination, and a contamination-associated event does not identify the intrinsic effect of pure NAD+. Read the actual FDA sterile-compounding warning. A January 2026 warning letter also found that NAD+ products at a particular outsourcing facility did not meet section 503B conditions. That specific finding should not be broadened into a statement that every jurisdiction treats every NAD-related product identically.
The five-day LNAD+ trial reported one mild nausea event in the active group. It did not establish long-term safety in people with kidney disease, cancer or other excluded conditions. The heart-failure trials involved supervised disease-specific care. Neither their results nor a research reagent’s analytical certificate makes an unsupervised injection or infusion equivalent to a studied preparation.
Does NAD+ feed cancer—or protect against it?
NAD metabolism supports normal cells and can also support malignant cells. The direction of an experimental result depends on the tumor model, molecule, tissue and intervention. A mouse study of NR reported more triple-negative breast-cancer development and brain metastasis, while a separate NAD+ study reported less metastasis in patient-derived tumor mouse models through a SIRT1-related mechanism.
These are not interchangeable exposures or evidence of cancer prevention in humans. They also do not provide a human cancer-risk percentage for supplementation. A blanket claim that NAD boosting is protective—or inherently safe because it supports DNA-related enzymes—goes beyond those experiments.
How to read NAD+ claims and analytical records
Start with the exact substance and formulation, then the sample and outcome. “NAD increased” may refer to total whole-blood NAD, oxidized NAD+ in one tissue, or a downstream metabolite. None automatically measures increased ATP production, improved symptoms or longer lifespan.
This also explains why combination reports need restraint. A 36-person uncontrolled long-COVID study combined low-dose naltrexone with NAD+ patches. Improvements after combined treatment cannot isolate the patch contribution, and the absence of a placebo comparison leaves other explanations open. It is not evidence for an NAD+ patch alone.
Keep chemistry, clinical outcomes and material quality separate
A biochemical mechanism can be well established while a treatment claim remains uncertain. A measured blood response can be real without a meaningful symptom benefit. A certificate can describe a particular laboratory material without demonstrating clinical efficacy or making it suitable for bodily use.
Three NAD+ report configurations, three separate records
The published Apex records illustrate the difference between chromatographic purity and measured active content. Detector-area percentage is not the fraction of the whole vial’s mass, and it should not be multiplied by a nominal label amount to invent an active-content result.
100 mg label configuration
July 29 record
99.953% integrated detector area
100.108 mg/vial active content
500 mg label configuration
July 30 record
99.930% integrated detector area
499.885 mg/vial active content
1,000 mg label configuration
July 31 record
99.959% integrated detector area
999.72 mg/vial active content
These are values from named Apex-issued reports, not a promise about which lot will ship. Match the supplied material’s identifier and specification to its applicable record. The COA reading guide explains how identity, detector-area purity, calibrated amount and other tests answer separate questions.
For related mechanisms, the MOTS-c guide discusses a mitochondrial-derived peptide, while the SS-31 guide covers a different mitochondrial-targeting compound. Neither is another name for NAD+.
Frequently Asked Questions About NAD+
What does NAD+ do in the body?
NAD+ helps transfer reducing equivalents in metabolism and is consumed by enzymes involved in signaling, protein regulation and DNA-damage responses. Its role in these reactions does not mean that adding more NAD+ automatically improves energy, cognition or lifespan.
Is NAD+ a peptide or a form of vitamin B3?
NAD+ is a dinucleotide coenzyme, not a peptide. Nicotinic acid and nicotinamide are vitamin B3 forms used in NAD synthesis. NR and NMN are related precursors, while NADH is the reduced redox partner of NAD+.
Does NAD+ supplementation really work?
Some tested interventions raise NAD-related blood measurements. Clinical effects depend on the exact substance, formulation, population and outcome. A 2026 trial of proprietary oral LNAD+ reported a total whole-blood NAD increase without a secondary clinical or wellbeing benefit surviving multiple-testing correction. This does not settle the effectiveness of every supplement.
Does NAD+ help with weight loss or belly fat?
The studies reviewed here do not establish direct NAD+ as a weight-loss treatment. A small NMN trial improved muscle insulin sensitivity in postmenopausal women with prediabetes without reducing weight, total fat or visceral fat. NMN is also a different intervention from direct NAD+.
Is NAD+ similar to Ozempic?
No. NAD+ is a metabolic coenzyme. Semaglutide, the active substance in Ozempic, is a GLP-1 receptor agonist. A coenzyme or precursor study cannot be used to claim the weight or glucose outcomes of a different medicine.
Is NAD+ better than NMN or NR?
There is no universal clinical ranking established by the evidence discussed here. NR and NMN can raise NAD-related measurements, and direct NAD+ studies now include specific randomized trials. Comparing the pathway position or blood-marker increase alone does not establish which intervention improves a particular health outcome.
What are the side effects of NAD+ injections or infusions?
Small studies describe gastrointestinal symptoms, increased heart rate and chest pressure during NAD+ infusion. FDA separately reports severe chills, shaking, vomiting and fatigue consistent with excessive endotoxin in some injectable products. These observations do not establish a universal rate, and contamination risk is distinct from intrinsic tolerability.
Does blood NAD+ always fall with age?
No uniform human whole-blood decline is established. A 2026 study across seven cohorts found whole-blood NAD+ stable with age and the studied lifestyle interventions. Other studies and tissues can show different patterns. A blood value should not automatically be treated as a biological-age score.
Does oral NAD+ enter cells intact?
The 2026 LNAD+ trial showed a whole-blood total-NAD response to a specific formulation, but did not use isotope tracing to distinguish intact NAD+ uptake from breakdown and resynthesis. It also did not establish delivery to brain, muscle or other tissues.
Does a high-purity NAD+ COA establish safety for human use?
No. An analytical report characterizes a named sample using specified methods. Detector-area purity, identity, active content and other tests are separate results. They do not establish clinical efficacy, appropriate administration or suitability of an Apex in-vitro research reagent for human use.
References and primary sources
Study sizes and results above refer to the named interventions. Reviews supply background and are not additional clinical trials. Regulatory pages, trial registrations and the named analytical records are linked where discussed.
- Kaeberlein M et al. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes & development. 1999. PMID 10521401.
- Vaziri H et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001. PMID 11672523.
- Howitz KT et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003. PMID 12939617.
- Pacholec M et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. The Journal of biological chemistry. 2010. PMID 20061378.
- Yoshino J et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell metabolism. 2011. PMID 21982712.
- Mouchiroud L et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell. 2013. PMID 23870130.
- Gomes AP et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013. PMID 24360282.
- Camacho-Pereira J et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell metabolism. 2016. PMID 27304511.
- Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature communications. 2016. PMID 27721479.
- Rajman L et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell metabolism. 2018. PMID 29514064.
- Conze D et al. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific reports. 2019. PMID 31278280.
- Grant R et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in aging neuroscience. 2019. PMID 31572171.
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science (New York, N.Y.). 2021. PMID 33888596.
- Brenner C et al. Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women". Science (New York, N.Y.). 2021. PMID 34326206.
- Klein S et al. Response to Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women". Science (New York, N.Y.). 2021. PMID 34326209.
- Reiten OK et al. Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing. Mechanisms of ageing and development. 2021. PMID 34517020.
- Yang F et al. Association of Human Whole Blood NAD+ Contents With Aging. Frontiers in endocrinology. 2022. PMID 35388296.
- Okabe K et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in nutrition. 2022. PMID 35479740.
- Maric T et al. A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism. Biosensors & bioelectronics. 2023. PMID 36371959.
- Jiang Y et al. NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling. Oncogene. 2023. PMID 36690678.
- Yaku K et al. NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Antioxidants & redox signaling. 2023. PMID 37335049.
- Isman A et al. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain, behavior, & immunity – health. 2024. PMID 38352659.
- McDermott MM et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature communications. 2024. PMID 38871717.
- Pei Z et al. Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure. Reviews in cardiovascular medicine. 2024. PMID 39228487.
- Yu X et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2026. PMID 40954388.
- Gao M et al. NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial. The Laryngoscope. 2026. PMID 41035311.
- Wu CY et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. 2025. PMID 41357333.
- Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature metabolism. 2026. PMID 41540253.
- Reyna K et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in aging. 2026. PMID 41704678.
- Trętowicz MM et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nature metabolism. 2026. PMID 42135539.
- Kornilov SA et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. GeroScience. 2026. PMID 42530810.
